


## NMS-859

|                    |   |       |         |
|--------------------|---|-------|---------|
| Cat. No.:          | HY-15714  |       |         |
| CAS No.:           | 1449236-96-7  |       |         |
| Molecular Formula: | C <sub>15</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>3</sub> S |       |         |
| Molecular Weight:  | 349.79  |       |         |
| Target:            | p97   |       |         |
| Pathway:           | Cell Cycle/DNA Damage   |       |         |
| Storage:           | Powder  | -20°C | 3 years |
|                    |   | 4°C   | 2 years |
|                    | In solvent  | -80°C | 2 years |
|                    |   | -20°C | 1 year  |



### SOLVENT & SOLUBILITY

|   |  |                          |              |            |            |
|---|--|--------------------------|--------------|------------|------------|
| In Vitro  | DMSO : 50 mg/mL (142.94 mM; Need ultrasonic)   |                          |              |            |            |
|   |  | Solvent<br>Concentration | Mass<br>1 mg | 5 mg       | 10 mg      |
|   | Preparing<br>Stock Solutions   | 1 mM                     | 2.8589 mL    | 14.2943 mL | 28.5886 mL |
|   |  | 5 mM                     | 0.5718 mL    | 2.8589 mL  | 5.7177 mL  |
| 10 mM   |  | 0.2859 mL                | 1.4294 mL    | 2.8589 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |  |                          |              |            |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline<br>Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution |                          |              |            |            |

### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC <sub>50</sub> s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.   |
| IC <sub>50</sub> & Target | IC <sub>50</sub> : 360 nM (Cellular p97, 1 mM ATP), 370 nM (Cellular p97, 60 μM ATP) <sup>[1]</sup>  |
| In Vitro                  | NMS-859 is a potent VCP inhibitor, with IC <sub>50</sub> s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively. NMS-859 shows very weak inhibitory activity against VCP <sup>C522T</sup> . NMS-859 also suppresses the proliferation of cells, with IC <sub>50</sub> s of 3.5 μM and 3.0 μM in HCT116 and HeLa cell lines, respectively <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

---

## PROTOCOL

### Cell Assay <sup>[1]</sup>

Cells are seeded at 1,600 cells per well in 384-well white clear-bottom plates. Twenty-four hours after seeding, cells are treated with NMS-859 (eight dilution points, in duplicate) and incubated for an additional 72 h at 37°C under a 5% CO<sub>2</sub> atmosphere. Cells are then lysed, and the ATP content in each well is determined using a thermostable firefly luciferase-based assay as a measure of cell viability. IC<sub>50</sub> values are calculated using the percentage of growth of treated cells versus the untreated control<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Sep;9(9):548-56.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA